Chan Heng Fai Ambrose's Form 4 filing
Impact Biomedical Inc. (IBO) · filed Apr 2, 2025
- Accession no.
- 0001641172-25-002479
- Filed
- Apr 2, 2025, 9:01 PM ET
- Trade date
- Mar 31-Apr 1, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $2.91M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chan Heng Fai AmbroseCIK 0001261725 | Director, 10% Owner |
| Alset International LtdCIK 0001660984 | 10% Owner |
| Alset Inc.CIK 0001750106 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | Common Stock | SSaleDisposed | −300,000 | $1.03 | −$308,400 | 1,253,904 | Indirect | |
| Apr 1, 2025 | Common stock | SSaleDisposed | −400,000 | $0.982 | −$392,800 | 853,904 | Indirect | |
| Apr 1, 2025 | Common Stock | SSaleDisposed | −650,000 | $1.45 | −$940,550 | 1,910,976 | Indirect | |
| Apr 1, 2025 | Common Stock | SSaleDisposed | −1,176,918 | $1.08 | −$1,271,071.44 | 734,058 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.